TrialBritish journal of clinical pharmacology2018

Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.

Sauzanne Khalilieh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.